Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
They need to make their own rules, their own guidelines in terms of what they're going to spend.
But if a new medication is developed and approved, and it takes the place of semaglutide, it will be harder and harder to find semaglutide at all
PNC
US$ 22.47
US$ 20.57
US$ 24.88
US$ 24.21
